DexCom, Inc. (NASDAQ:DXCM) Receives $84.83 Consensus Target Price from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been assigned an average rating of “Moderate Buy” from the twenty-six brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $84.8333.

A number of research firms have recently commented on DXCM. Stifel Nicolaus set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, June 5th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a research report on Tuesday, March 24th. Barclays reissued an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. TD Cowen restated a “buy” rating and issued a $95.00 price target (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Finally, Bank of America reduced their price target on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th.

Insider Activity at DexCom

In other news, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the transaction, the executive vice president owned 100,361 shares of the company’s stock, valued at approximately $7,326,353. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock worth $3,343,977 in the last three months. Insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several large investors have recently added to or reduced their stakes in DXCM. Reflection Asset Management acquired a new stake in DexCom in the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new stake in DexCom during the first quarter worth $25,000. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the period. MCF Advisors LLC bought a new stake in shares of DexCom in the fourth quarter valued at $32,000. Finally, ORG Partners LLC grew its position in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $72.47 on Wednesday. The business’s 50-day simple moving average is $67.07 and its 200 day simple moving average is $67.92. The stock has a market cap of $27.96 billion, a price-to-earnings ratio of 30.97, a P/E/G ratio of 1.13 and a beta of 1.45. DexCom has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the business earned $0.32 earnings per share. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. As a group, research analysts anticipate that DexCom will post 2.58 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.